Natera price target raised to $200 from $160 at Bernstein

Bernstein raised the firm’s price target on Natera (NTRA) to $200 from $160 and keeps an Outperform rating on the shares. The 2025 setup for life science tools “feels a little bit like deja vu all over again,” the analyst tells investors in a research note. The firm says the idea that the recovery is starting, and should see progressive improvement throughout the year, “could be copy / pasted from most 2024 outlooks.” However, this time around, Bernstein says there is more reason to be optimistic. The firm is starting to see “real signs of recovery,” with biotech funding up, China stimulus is starting to flow, and indicators that pressure on instruments may be easing.